Nothing Special   »   [go: up one dir, main page]

IL150374A0 - Compounds and methods for modulating cerebral amyloid angiopathy - Google Patents

Compounds and methods for modulating cerebral amyloid angiopathy

Info

Publication number
IL150374A0
IL150374A0 IL15037400A IL15037400A IL150374A0 IL 150374 A0 IL150374 A0 IL 150374A0 IL 15037400 A IL15037400 A IL 15037400A IL 15037400 A IL15037400 A IL 15037400A IL 150374 A0 IL150374 A0 IL 150374A0
Authority
IL
Israel
Prior art keywords
compounds
methods
amyloid angiopathy
cerebral amyloid
modulating
Prior art date
Application number
IL15037400A
Other languages
English (en)
Original Assignee
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Inc filed Critical Neurochem Inc
Publication of IL150374A0 publication Critical patent/IL150374A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15037400A 1999-12-23 2000-12-22 Compounds and methods for modulating cerebral amyloid angiopathy IL150374A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17187799P 1999-12-23 1999-12-23
PCT/IB2000/002078 WO2001085093A2 (en) 1999-12-23 2000-12-22 Compounds and methods for modulating cerebral amyloid angiopathy

Publications (1)

Publication Number Publication Date
IL150374A0 true IL150374A0 (en) 2002-12-01

Family

ID=22625484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15037400A IL150374A0 (en) 1999-12-23 2000-12-22 Compounds and methods for modulating cerebral amyloid angiopathy

Country Status (11)

Country Link
US (2) US6670399B2 (zh)
EP (1) EP1251837A2 (zh)
JP (1) JP2003532656A (zh)
KR (3) KR20090016517A (zh)
CN (1) CN1434706A (zh)
AU (1) AU8431301A (zh)
BR (1) BR0016652A (zh)
CA (1) CA2395314A1 (zh)
IL (1) IL150374A0 (zh)
MX (1) MXPA02006196A (zh)
WO (1) WO2001085093A2 (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
AU5994900A (en) * 1999-07-09 2001-01-30 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20050107345A1 (en) * 2002-03-01 2005-05-19 Doherty George A. Aminoalkylphosphonates and related compounds as edg receptor agonists
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1477493A1 (en) * 2003-05-15 2004-11-17 Bayer HealthCare AG Isotope coded affinity tags
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2529269C (en) * 2003-06-23 2012-02-07 Neurochem (International) Limited Improved pharmaceutical drug candidates and methods for preparation thereof
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP5146714B2 (ja) * 2003-06-23 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2007049098A2 (en) * 2004-06-18 2007-05-03 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1765781A2 (en) 2004-07-09 2007-03-28 Sigma-Aldrich Co. Optically enhanced chiral ionic liquids
CA2574460A1 (en) 2004-07-23 2006-02-02 Sigma-Aldrich Co. High stability diionic liquid salts
US8168830B2 (en) 2004-07-23 2012-05-01 Sigma-Aldrich Co. Llc High stability diionic liquid salts
US20090215717A1 (en) * 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
WO2006059245A2 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
JP2008535907A (ja) * 2005-04-12 2008-09-04 ニユーロケム（インターナショナル）、リミテッド アミロイド阻害化合物の薬学的製剤
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
EP3851447B1 (en) 2006-10-12 2023-09-06 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008070284A2 (en) * 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010513219A (ja) * 2006-12-22 2010-04-30 ベラス ヘルス （インターナショナル） リミテッド 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療
WO2008095069A2 (en) * 2007-01-31 2008-08-07 Sigma-Aldrich Co. High stability polyionic liquid salts
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
GB0708507D0 (en) * 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2183258A2 (en) * 2007-08-01 2010-05-12 Centre National de la Recherche Scientifique (CNRS) Thiophosphi(o)nic acid derivatives and their use as agonists or antagonists for metabotropic glutamate receptors
US20090076167A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched tramiprosate
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
EP2180003A1 (en) * 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
EP2464626A4 (en) 2009-08-10 2015-12-16 Bhi Ltd Partnership PROCESSES, COMPOUNDS AND COMPOSITIONS FOR THE EXPORTS OF 1,3-PROPANE-SULFONIC ACID
EP2289900A1 (en) * 2009-08-26 2011-03-02 Humboldt Universität zu Berlin Bisphosphonates as inhibitors of acid sphingomyelinase
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
WO2012033831A2 (en) 2010-09-07 2012-03-15 Memorial Sloan-Kettering Cancer Center Methods and compositions for gamma-secretase assay
US12085575B2 (en) 2011-12-01 2024-09-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting proteinopathies
US10962553B2 (en) 2011-12-01 2021-03-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for detecting proteinopathies
US9599626B2 (en) * 2011-12-01 2017-03-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic and diagnostic method for ataxia-telangiectasia
WO2013158846A1 (en) * 2012-04-20 2013-10-24 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
CN102793694B (zh) * 2012-08-14 2014-06-04 武汉华纳联合药业有限公司 3-氨基-1-丙烷磺酸及其衍生物在制备治疗脑卒中的药物中的应用
JP5804463B2 (ja) * 2012-12-27 2015-11-04 国立研究開発法人科学技術振興機構 環状ペプチド及びこれを含有する医薬
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110520432B (zh) * 2017-04-17 2022-08-02 株式会社Nahls 光学活性的2－氨基－膦酰基烷酸、光学活性的2－氨基－膦酰基烷酸盐及它们的水合物
RU2696684C1 (ru) * 2018-09-18 2019-08-05 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ определения типов когнитивных расстройств у больных церебральной микроангиопатией

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5972328A (en) 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
WO1994027602A1 (en) 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
ES2188652T3 (es) * 1994-02-28 2003-07-01 Nanopharm Ag Sistema de direccionado de farmacos, metodos de fabricacion y uso del mismo.
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5514653A (en) 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
DE4434654C2 (de) 1994-09-28 1996-10-10 Arburg Gmbh & Co Verfahren zur Beeinflussung zyklisch ablaufender Prozesse
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU5585198A (en) 1996-11-22 1998-06-10 Athena Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and ethods for inhibiting beta-amyloid peptide release and/or its synthesis
CA2267065A1 (en) 1996-11-22 1998-05-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositionscomprising same, and methods for inhibiting beta-amyloid peptide release a nd/or its synthesis by use of such compounds
PE27799A1 (es) * 1996-12-10 1999-03-18 Novartis Ag Formulaciones y formas polimorficas de desferrioxamina y su preparacion
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
WO1999008685A1 (en) * 1997-08-18 1999-02-25 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
DK1054664T3 (da) * 1998-02-11 2012-11-05 Bhi Ltd Partnership Fremgangsmåde til modulering af makrofagaktivering
WO1999059571A1 (en) 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
PT1083889E (pt) 1998-06-01 2004-04-30 Ortho Mcneil Pharm Inc Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
US6586475B1 (en) * 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
DE60037800D1 (de) 1999-05-05 2008-03-06 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
WO2001085093A2 (en) * 1999-12-23 2001-11-15 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy

Also Published As

Publication number Publication date
MXPA02006196A (es) 2002-12-09
US6670399B2 (en) 2003-12-30
US20080317834A1 (en) 2008-12-25
WO2001085093A2 (en) 2001-11-15
WO2001085093A9 (en) 2002-09-26
KR20090016517A (ko) 2009-02-13
US20030003141A1 (en) 2003-01-02
EP1251837A2 (en) 2002-10-30
CN1434706A (zh) 2003-08-06
AU8431301A (en) 2001-11-20
WO2001085093A3 (en) 2002-08-29
JP2003532656A (ja) 2003-11-05
CA2395314A1 (en) 2001-11-15
KR20020063266A (ko) 2002-08-01
KR20080003945A (ko) 2008-01-08
BR0016652A (pt) 2002-11-19

Similar Documents

Publication Publication Date Title
IL150374A0 (en) Compounds and methods for modulating cerebral amyloid angiopathy
EP1223932A4 (en) COMPOUNDS AND METHODS
EP1146790A4 (en) COMPOUNDS AND METHODS
GB0118297D0 (en) Synthetic closure
AU142485S (en) Closure
GB2333256B (en) Disk locking device
HK1037590A1 (en) An indirectly activated closure
PL350298A1 (en) Tamper evident closure
HK1031156A1 (en) Engagement device capable of readily integrating two members
GB9915273D0 (en) Closure
HUP0201647A2 (en) Screening methods for compounds that affect melanogenesis
GB9919964D0 (en) Closure elements
GB2350989B (en) Background-noise reduction
GB2352714B (en) Tamper evident closure
AU142192S (en) Closure
GB2351755B (en) Safety gate
GB2342139B (en) Closure
GB9904001D0 (en) Radiotelephone buzzer
CA85715S (en) Flip-cap closure
GB9917366D0 (en) Easy fit closure
GB9923117D0 (en) Insect-paper and methods for its formation and use
IL133804A0 (en) Closure for shutter
GB9904548D0 (en) Closure
AU139799S (en) Closure
GB9919349D0 (en) Closure